Cytosorbents Corporation
Cytosorbents Corporation (CTSO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ctso · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cytosorbents Corporation (CTSO) measures how much investors pay for each dollar of the company's trailing earnings. CTSO's current PE ratio of N/A is calculated by dividing its stock price of $0.41 by its TTM earnings per share of -$0.19.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cytosorbents CorporationYou CTSO | $26M | N/A | — | -$0.19 |
 Baird Medical Investment Holdings Limited BDMD | $52M | N/A | — | -$0.98 |
 Biodesix, Inc. BDSX | $122M | N/A | — | -$4.67 |
 electroCore, Inc. ECOR | $80M | N/A | — | -$1.65 |
 IceCure Medical Ltd ICCM | $8M | N/A | — | -$7.10 |
 Spectral AI, Inc. MDAI | $59M | N/A | — | -$0.29 |
 NeuroOne Medical Technologies Corporation NMTC | $30M | N/A | — | -$0.54 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.13 | — | |
2024-12-31 FY2024 | — | $-0.38 | — | |
2023-12-31 FY2023 | — | $-0.65 | — | |
2022-12-31 FY2022 | — | $-0.75 | — | |
2021-12-31 FY2021 | — | $-0.57 | — | |
2020-12-31 FY2020 | — | $-0.20 | — | |
2019-12-31 FY2019 | — | $-0.60 | — | |
2018-12-31 FY2018 | — | $-0.56 | — | |
2017-12-31 FY2017 | — | $-0.31 | — | |
2016-12-31 FY2016 | — | $-0.47 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cytosorbents Corporation (CTSO) measures how much investors pay for each dollar of the company's trailing earnings. CTSO's current PE ratio of N/A is calculated by dividing its stock price of $0.41 by its TTM earnings per share of -$0.19.
Frequently asked questions
CTSO pe ratio · 6 questionsCTSO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.41 and TTM EPS of -$0.19. Data sourced from Financial Modeling Prep via CTSO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cytosorbents Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09